GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Helix BioMedix HXBM · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.29

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$807,193

FY2014FY2025

Net income

−$551,512

FY2014FY2025

Free cash flow

−$601,070

FY2014FY2025

Shareholders' equity

$1.5m

FY2014FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2014
Revenue$807,193$804,229$997,726$1.8m$2.4m$1.8m$1.8m
Research and development$176,611$510,596$317,062$891,961$1.2m$1.0m—
Operating income−$595,812−$1.1m−$984,053−$1.1m−$1.3m−$1.2m—
Net income−$551,512−$982,339−$1.1m−$1.2m−$1.4m−$1.9m—
Diluted earnings per share-2.45-4.37-4.70-5.31-6.05-8.25—

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2014
Total assets$1.7m$2.2m$3.0m$3.9m$4.8m$5.6m—
Cash and short-term investments$1.3m$1.9m$2.6m$3.4m$4.2m$4.9m—
Total liabilities$137,626$127,779$66,929$126,243$107,589$3.4m—
Debt———$71,200—$2.9m—
Shareholders' equity$1.5m$2.1m$3.0m$3.8m$4.7m$2.2m—
Shares outstanding0m0m0m0m0m0m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2014
Cash from operations−$601,067—−$870,209−$727,732−$854,672−$667,328—
Capital spending−$3—−$1,318−$1,345−$7,598−$41,132—
Free cash flow−$601,070—−$871,527−$729,077−$862,270−$708,460—

Latest quarters

By quarter end

Sept 2016Jun 2016Mar 2016Dec 2015Sept 2015Jun 2015Mar 2015Dec 2014
Revenue$563,000$789,000$958,000$923,000$774,000$568,000$289,000$367,000

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-22.8%-15.2%-0.5%
Operating income-18.0%-13.5%-14.8%
Net income-22.7%-21.5%-23.2%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-103.0%-85.3%-73.2%—
Net margin-95.2%-86.7%-81.6%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2014FY2013FY2012
Price to earnings-0.2-0.4-1.0-0.9-0.4-0.3———
Price to sales0.10.51.10.60.20.30.30.30.1

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-77%-48%-10%117%0%-6%-11%0%0%1%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 300-to-1 reverse split · 3 Jan 2013

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.